Recently, the FDA authorized NMN for investigation as a new drug which means, according to its own rules, it cannot be sold as a dietary supplement at the same time. This caused a backlash, including from Council for Responsible Nutrition (CRN) which highlighted that the agency had acknowledged a New Dietary Ingredient Notification for β-NMN without objection and had not previously raised any concerns publicly about the ingredient being used in dietary supplements.
- In addition to the FDA, some criticism was directed towards David Sinclair who co-founded MetroBiotech (and remains the chair of its scientific advisory board) which initiated the application for NMN's new status. He has now responded on Twitter, with the following key points:
- I am not, and have not, been involved as an owner, cofounder, investor, shareholder, marketer, spokesperson or sponsor of any company that sells NAD boosters as supplements.
- MetroBiotech [is] a company I co-founded but do not manage or control
- the company had begun clinical trials with a special, crystalline form of NMN that is stable and made under FDA drug standards
- I remain enthusiastic about the science of NAD boosters and their promise of improving human health
- Furthering that science, and the prospect of cellular age reversal, continues to be my life’s work
- Human clinical trials conducted by MetroBiotech on NMN have produced promising results
- bringing NMN to market as an FDA-approved medication is in the best interest
